Evidence map›Paper›PMID 40903192›Full record

ReviewJournal for immunotherapy of cancer2025

m

Parmanand Malvi, Patrick Ball, Romi Gupta, Narendra Wajapeyee

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Parmanand MalviDepartment of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Patrick BallDepartment of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Romi GuptaDepartment of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Narendra WajapeyeeDepartment of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, Alabama, USA nwajapey@uab.edu.

Funding

Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinomaR01CA257046 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WAJAPEYEE, NARENDRA · 2021 to 2025
$2.3M
Targeting melanoma promoting RNA modification pathway for melanoma therapy.R01CA295454 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Narendra Wajapeyee · 2025 to 2026
$884k
NCI NIH HHS R01 CA257046NCI NIH HHS R01 CA295454
6 · The paper itself

Abstract

RNA molecules are subject to extensive post-transcriptional modifications that fine-tune their stability, localization, and function. Among the more than 100 known RNA modifications, N6-methyladenosine (m

Indexed as

AdenosineImmunologic SurveillanceNeoplasmsTranscriptomeAnimalsHumansRNA Processing, Post-TranscriptionalAdenosineN-methyladenosineGeneticGenomeImmune Checkpoint InhibitorImmunotherapy

Identifiers

PMID40903192
PMCPMC12410683

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.